#4 - Pfizer (NYSE:PFE)
Pfizer Inc. (NYSE: PFE) is another company that’s trying to throw its hat into the GLP-1 arena. In this case, Pfizer is attempting to advance several candidates through its pipeline. As of this writing, the company is advancing danuglipron, which it believes may be the one that makes it to market.
Danuglipron is an oral GLP-1 drug that would be taken daily. Pfizer is hoping that the convenience of taking the medicine in pill form will negate any possible pushback from customers having to take the drug every day.
Like the offering from Amgen, danuglipron is still in clinical trials. And by the time it’s approved (if it makes it that far), it’s unclear what the competitive landscape may look like. However, while you wait, you’ll own an attractive dividend stock. PFE stock pays investors a yield of 5.9% and has been increasing its payout for 15 consecutive years. With a forward price-to-earnings ratio of just 10.69x, the company is undervalued compared to the 18.7 sector average for pharmaceutical stocks in the S&P 500.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More - Current Price
- $26.21
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $32.92 (25.6% Upside)
